(ATI/HESI question from external source) Which statement is true regarding hepatitis A vaccine?

Choice A rationale:

Monitoring vital signs and mental status is crucial in patients with suspected hepatitis as they may develop complications such as hepatic encephalopathy, which can lead to changes in mental status.

Choice B rationale:

Administering prescribed medications and fluids is important to support the patient's liver function and manage symptoms of hepatitis. Antiviral medications may be used to treat certain types of viral hepatitis.

Choice C rationale:

Educating the patient about hepatitis vaccines is not applicable in a patient with suspected hepatitis since vaccines are used for prevention and are not effective in treating an ongoing infection.

Choice D rationale:

Encouraging the patient to engage in high-impact exercise is not recommended in patients with suspected hepatitis, as strenuous physical activity may worsen hepatic injury or lead to complications.

Choice E rationale:

Implementing infection control measures to prevent transmission is crucial in suspected hepatitis cases, as the disease can spread through contact with contaminated blood or body fluids. Standard precautions should be followed to prevent healthcare-associated infections and protect others from contracting the virus.

Choice A rationale:

The client's statement, "I will take pegylated interferon-alpha as the antiviral agent," demonstrates understanding of the treatment regimen for chronic hepatitis

D. Pegylated interferon-alpha is the recommended antiviral therapy for chronic hepatitis

D. It helps suppress viral replication and reduce liver inflammation, which is essential in managing the disease. Interferon therapy can be used alone or in combination with antiviral agents like lamivudine or adefovir. However, it is crucial to note that interferon therapy may have side effects, and the client should be educated about them.

Choice B rationale:

"I will use ribavirin to suppress viral replication" is incorrect. Ribavirin is an antiviral agent used for the treatment of hepatitis C but is not typically recommended for hepatitis

D. The primary antiviral therapy for hepatitis D is pegylated interferon-alpha.

Choice C rationale:

"I need to continue the treatment for a shorter duration than hepatitis B or C" is incorrect. The treatment duration for chronic hepatitis D is generally longer than that for hepatitis B or

C. The therapy may last for six months to a year or even longer, depending on the individual response to treatment and the level of liver damage.

Choice D rationale:

"The goal of treatment is to achieve undetectable HDV RNA after the treatment ends" is incorrect. While achieving undetectable HDV RNA is a favorable outcome, it may not always be achievable with current therapies. The primary goal of treatment is to suppress viral replication, reduce liver inflammation, and slow down the progression of liver disease.